Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma (Q36868642)

16 August 2017

0 references

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma (English)

1 reference

16 August 2017

1 reference

Ravi Salgia

1 reference

16 August 2017

Rajani Kanteti

1 reference

16 August 2017

Keith Wilner

1 reference

16 August 2017

D Ross Camidge

1 reference

16 August 2017

James G Christensen

1 reference

16 August 2017

Marileila Varella-Garcia

object named as

Marileila Varella-Garcia

1 reference

16 August 2017

Jennifer R Diamond

1 reference

16 August 2017

Patricia M LoRusso

1 reference

16 August 2017

Jeffrey W Clark

1 reference

16 August 2017

Ling-Guo Xu

1 reference

16 August 2017

S Gail Eckhardt

1 reference

16 August 2017

Keith A Ching

1 reference

16 August 2017

Maruja E Lira

1 reference

16 August 2017

Eric F P M Schoenmakers

1 reference

16 August 2017

language of work or name

English

0 references

publication date

22 April 2013

1 reference

Journal of Clinical Oncology

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

e254-8

1 reference

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

XL184 (cabozantinib) for medullary thyroid carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Targeting the HGF/Met signalling pathway in cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Ethnic differences and functional analysis of MET mutations in lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Contemporary epidemiology of renal cell cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Contemporary approach to the classification of renal epithelial tumors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Activating mutations for the Met tyrosine kinase receptor in human cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Two mutations affecting conserved residues in the Met receptor operate via different mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661938

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23610116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23610116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2012.46.4289

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

23610116

1 reference